Mahadevia Ankit
SEC insider (Form 3/4/5 filer). CIK 0001720974. Director at Spero Therapeutics, Inc. (SPRO). 4 reported Form 4/5 transactions since Sep 2024; latest on Aug 28, 2025. Located in CAMBRIDGE, MA.
Companies Mahadevia Ankit has filed insider reports for
- Spero Therapeutics, Inc. (SPRO): Director
Mahadevia Ankit
CIK: 0001720974
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)3 (75.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (25.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
SPRO
Spero Therapeutics, Inc.
Director
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Aug 28, 2025SPRO
Spero Therapeutics, Inc.
SaleDirect6.6K shares at avg. $1.97$13K - Jun 12, 2025SPRO
Spero Therapeutics, Inc.
AwardDirect20K shares- - Feb 5, 2025SPRO
Spero Therapeutics, Inc.
SaleDirect14K shares at avg. $0.78$11K - Feb 5, 2025SPRO
Spero Therapeutics, Inc.
SaleDirect55.3K shares at avg. $0.78$43K
1-4 of 4 transactions